Prostate Cancer

An updated analysis of the results of a phase III clinical trial showed that radium-223 dichloride (Xofigo) significantly improved overall survival and delayed time to the first skeletal-related event in patients with metastatic prostate cancer.

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes the Prostate Health Cocktail.

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

At the 2013 ASCO Annual Meeting, researchers presented the latest developments with enzalutamide, radium-223, and abiraterone acetate as treatments for patients with advanced prostate cancer.

Amid a flurry of new drug approvals, the AUA has issued its first set of guidelines for the management of patients with mCRPC, which included an extensive role for abiraterone acetate at several stages of the disease.

An assay based on a prostate-specific antigen isoform performed significantly better than did conventional PSA measures for detecting prostate cancer and identifying histopathologically aggressive cancers.

Investigators say they have found no association between the use of 5-alpha-reductase inhibitors (5ARIs) and the risk of developing high-grade or lethal prostate cancer.

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.

Neal D. Shore, MD, FACS, discusses an analysis of degarelix and luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer.

Daniel J. George, MD, from the Duke Cancer Institute, discusses the potential to incorporate radium-223 into combination strategies to treat patients with metastatic castation-resistant prostate cancer.

Alterations in the chromosomes of two genes have been implicated in an increased risk of prostate cancer mortality, and the discovery holds promise for distinguishing which patients are candidates for more aggressive therapy.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.